UY24861A1 - Derivados de sulfonilurea - Google Patents
Derivados de sulfonilureaInfo
- Publication number
- UY24861A1 UY24861A1 UY24861A UY24861A UY24861A1 UY 24861 A1 UY24861 A1 UY 24861A1 UY 24861 A UY24861 A UY 24861A UY 24861 A UY24861 A UY 24861A UY 24861 A1 UY24861 A1 UY 24861A1
- Authority
- UY
- Uruguay
- Prior art keywords
- general formula
- chloro
- urea
- acute
- phenyl
- Prior art date
Links
- GQSFASWYVBMKSL-UHFFFAOYSA-N 1-methyl-3-methylsulfonylurea Chemical class CNC(=O)NS(C)(=O)=O GQSFASWYVBMKSL-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- YRSBLSHMKVQWHP-UHFFFAOYSA-N 1-[4-chloro-2,6-di(propan-2-yl)phenyl]-3-[3-(2-hydroxypropan-2-yl)phenyl]sulfonylurea Chemical compound CC(C)C1=CC(Cl)=CC(C(C)C)=C1NC(=O)NS(=O)(=O)C1=CC=CC(C(C)(C)O)=C1 YRSBLSHMKVQWHP-UHFFFAOYSA-N 0.000 abstract 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 201000009906 Meningitis Diseases 0.000 abstract 1
- 208000009525 Myocarditis Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 1
- 208000007893 Salpingitis Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000038016 acute inflammation Diseases 0.000 abstract 1
- 230000006022 acute inflammation Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 208000003167 cholangitis Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 abstract 1
- 206010014599 encephalitis Diseases 0.000 abstract 1
- 206010014665 endocarditis Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000008494 pericarditis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composición farmacéutica útil en el tratamiento de la meningitis y salpingitis, choque séptico, coagulación intravascular diseminada, y/o el síndrome de distrés respiratorio en adultos, inflamación aguda o crónica, artritis, colangitis, colitis, encefalitis, endocarditis, glomerulonefritis, hepatitis, miocarditis, pancreatitis, pericarditis, lesiones por reperfusión, vasculitis, hipersensibilidad aguda y retardada, rechazo de injertos, y enfermedad del huésped frente al injerto, enfermedades autoinmunes que incluyen diabetes mellitus del tipo I y la esclerosis múltiple, enfermedades peridonatas y otras; que comprende una cantidad eficaz de un compuesto de fórmula general (I) representada en la figura 1, o una sal farmacéuticamente aceptable del mismo, donde: R1 y R2 son cada uno de ellos independientemente un grupo de fórmula general representado en la figura 2, donde las líneas de trazos representan enlaces dobles opcionales, y n es 0 o 1, con la condición de cuando n es 1 entonces A, B, D, E Y son cada CR5, y cuando n es 0, entonces G es O o S y A hasta E son cada uno CR5. Ejemplos no limitantes de compuestos de fórmula general (I): 1-(4-cloro-2,6-diisopropil-fenil)-3-[3-(1-hidroxi-1-metiletil)bencenosulfonil]urea; 1-(4-cloro-2,6-disopropil-fenil)-3-[3-metilsulfamoil-bencenosulfunil]urea.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3697997P | 1997-01-29 | 1997-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY24861A1 true UY24861A1 (es) | 2000-09-29 |
Family
ID=21891776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY24861A UY24861A1 (es) | 1997-01-29 | 1998-01-20 | Derivados de sulfonilurea |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US6166064A (es) |
| EP (1) | EP0964849B1 (es) |
| JP (1) | JP3573757B2 (es) |
| KR (1) | KR100324058B1 (es) |
| CN (1) | CN1127479C (es) |
| AP (1) | AP929A (es) |
| AR (1) | AR011093A1 (es) |
| AT (2) | ATE242208T1 (es) |
| AU (1) | AU723895B2 (es) |
| BG (1) | BG103597A (es) |
| BR (1) | BR9714328A (es) |
| CA (1) | CA2279186C (es) |
| CO (1) | CO4920230A1 (es) |
| CZ (1) | CZ293173B6 (es) |
| DE (2) | DE69722663T2 (es) |
| DK (2) | DK0964849T3 (es) |
| DZ (1) | DZ2407A1 (es) |
| EA (1) | EA001803B1 (es) |
| ES (2) | ES2222426T3 (es) |
| HR (1) | HRP980045B1 (es) |
| HU (1) | HUP0000567A3 (es) |
| ID (1) | ID22223A (es) |
| IL (1) | IL130855A0 (es) |
| IS (1) | IS5099A (es) |
| MA (1) | MA26468A1 (es) |
| NO (1) | NO313279B1 (es) |
| NZ (1) | NZ336248A (es) |
| OA (1) | OA11079A (es) |
| PA (1) | PA8444701A1 (es) |
| PE (1) | PE57898A1 (es) |
| PL (1) | PL335052A1 (es) |
| PT (2) | PT1270565E (es) |
| SK (1) | SK283679B6 (es) |
| TN (1) | TNSN98017A1 (es) |
| TR (1) | TR199901816T2 (es) |
| TW (1) | TW515788B (es) |
| UY (1) | UY24861A1 (es) |
| WO (1) | WO1998032733A1 (es) |
| YU (1) | YU33799A (es) |
| ZA (1) | ZA98685B (es) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022984A (en) * | 1998-07-27 | 2000-02-08 | Pfizer Inc. | Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors |
| EP1526383A3 (en) * | 1998-08-31 | 2005-11-16 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
| IT1303249B1 (it) * | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| BR0014003A (pt) * | 1999-09-14 | 2002-05-21 | Pfizer Prod Inc | Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| RS54274B1 (en) | 2001-06-26 | 2016-02-29 | Amgen Fremont Inc. | Opgl antibodies |
| MXPA04001785A (es) | 2001-09-14 | 2004-07-08 | Bayer Ag | Benzofurano y derivados de dihidrobenzofurano utiles como agonistas de beta-3 adrenoreceptores. |
| EP1487457A1 (en) * | 2001-11-30 | 2004-12-22 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| US20030131370A1 (en) * | 2001-12-14 | 2003-07-10 | Pfizer Inc. | Disruption of the glutathione S-transferase-Omega-1 gene |
| ATE349210T1 (de) | 2002-07-09 | 2007-01-15 | Boehringer Ingelheim Pharma | Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege |
| CA2497884C (en) | 2002-09-06 | 2013-10-22 | Brian Varnum | Therapeutic human anti-il-1r1 monoclonal antibody |
| AU2003263560A1 (en) * | 2002-10-03 | 2004-04-23 | Pfizer Products Inc. | Use of gst-omega-2 as a therapeutic target |
| SG145745A1 (en) | 2003-08-06 | 2008-09-29 | Senomyx Inc | Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
| DE602005016937D1 (de) * | 2004-03-23 | 2009-11-12 | Dompe Pha R Ma Spa Res & Mfg | Pharmazeutische zusammensetzung |
| US20060045953A1 (en) * | 2004-08-06 | 2006-03-02 | Catherine Tachdjian | Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| MY158077A (en) | 2005-02-04 | 2016-08-30 | Senomyx Inc | Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers tastants and taste enhancers for comestible compositions |
| WO2006090921A1 (ja) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | スルホンアミド化合物のリンパ球活性化抑制作用 |
| US7208526B2 (en) * | 2005-05-20 | 2007-04-24 | Hoffmann-La Roche Inc. | Styrylsulfonamides |
| TW200715993A (en) | 2005-06-15 | 2007-05-01 | Senomyx Inc | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers |
| TWI674069B (zh) | 2006-04-21 | 2019-10-11 | 美商賽諾米克斯公司 | 包含高度鮮味風味劑之可食用組合物及其製造方法 |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| US7973051B2 (en) * | 2007-11-30 | 2011-07-05 | Hoffman-La Roche Inc. | Aminothiazoles as FBPase inhibitors for diabetes |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| CA2957566C (en) | 2014-08-12 | 2023-08-01 | Daniel Paul Becker | Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same |
| RS62164B1 (sr) * | 2015-02-16 | 2021-08-31 | Univ Queensland | Sulfoniluree i srodna jedinjenja i njihova upotreba |
| US10688077B2 (en) * | 2015-02-26 | 2020-06-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inflammasome activation in myelodysplastic syndromes |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| CA3014487A1 (en) | 2016-02-16 | 2017-08-24 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Sulfonylureas and related compounds and use of same |
| ES2940611T3 (es) * | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| WO2017184624A1 (en) | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
| EP3272739A1 (en) * | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| US20220267260A1 (en) * | 2016-11-29 | 2022-08-25 | Epizyme, Inc. | Compounds containing a sulfonic group as kat inhibitors |
| UA126675C2 (uk) | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| CA3059458A1 (en) * | 2017-05-24 | 2018-11-29 | The University Of Queensland | Novel compounds and uses |
| EP3634951B8 (en) | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| KR102669722B1 (ko) | 2017-07-07 | 2024-05-29 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| PL3658539T3 (pl) | 2017-07-24 | 2024-07-01 | Novartis Ag | Związki i kompozycje do leczenia stanów związanych z aktywnością nlrp |
| MX2020001778A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida. |
| UY37847A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| US11518739B2 (en) | 2017-08-15 | 2022-12-06 | Inflazome Limited | Sulfonamide carboxamide compounds |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| US11718631B2 (en) | 2017-10-17 | 2023-08-08 | Novartis Ag | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity |
| EP3707137A1 (en) | 2017-11-09 | 2020-09-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| PE20210050A1 (es) | 2017-11-09 | 2021-01-08 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| CN108299256B (zh) * | 2018-01-09 | 2019-09-10 | 武汉大学 | 一类2,3,4-三羟基苯磺酰胺衍生物及其制备方法和应用 |
| EP3759078A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166629A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| WO2019166627A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| US11530200B2 (en) | 2018-03-02 | 2022-12-20 | Inflazome Limited | Compounds |
| US12168653B2 (en) | 2018-03-02 | 2024-12-17 | Inflazome Limited | Sulfonamide derivates as NLRP3 inhibitors |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| US20220267276A1 (en) | 2018-07-03 | 2022-08-25 | Novartis Ag | Nlrp modulators |
| WO2020018970A1 (en) * | 2018-07-20 | 2020-01-23 | Genentech, Inc. | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| US20210236599A1 (en) | 2018-08-13 | 2021-08-05 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| MA53221A (fr) | 2018-08-15 | 2022-04-27 | Inflazome Ltd | Nouveaux composés de sulfonamide urée |
| JP2022505525A (ja) * | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| DK3911631T3 (da) | 2019-01-14 | 2025-02-03 | Zydus Lifesciences Ltd | Hidtil ukendte, substituerede sulfonylureaderivater |
| PT3983387T (pt) | 2019-06-12 | 2024-07-10 | Nodthera Ltd | Derivados de sulfonilurea e seus usos |
| EP3986879B1 (en) | 2019-06-21 | 2024-10-02 | AC Immune SA | Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators |
| CN114746087A (zh) * | 2019-09-12 | 2022-07-12 | 载度思生命科学有限公司 | 新的经取代的亚砜亚胺衍生物 |
| JP7504234B2 (ja) * | 2020-06-11 | 2024-06-21 | シーセン ファーマシューティカル カンパニー リミテッド | ジメチルスルホキシミン誘導体 |
| AU2021291065A1 (en) | 2020-06-19 | 2022-12-15 | Ac Immune Sa | Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway |
| WO2022022646A1 (zh) * | 2020-07-29 | 2022-02-03 | 南京明德新药研发有限公司 | 含硒五元杂芳环化合物 |
| BR112023003792A2 (pt) | 2020-09-04 | 2023-03-28 | Nodthera Ltd | Derivados de sulfamoil ureia contendo porção alquil-oxacicloalquila e usos dos mesmos |
| ES2948511A1 (es) * | 2021-09-08 | 2023-09-13 | Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa | Derivados de n-sulfonilureas y su uso terapeutico |
| CN118355000A (zh) * | 2021-12-03 | 2024-07-16 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物的盐型及晶型 |
| EP4452972A1 (en) | 2021-12-22 | 2024-10-30 | AC Immune SA | Dihydro-oxazol derivative compounds |
| CN118871426A (zh) * | 2022-02-15 | 2024-10-29 | 豪夫迈·罗氏有限公司 | 用于制备1,2,3,5,6,7-六氢-s-二环戊二烯并苯衍生物的方法 |
| WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
| US20240034735A1 (en) | 2022-07-14 | 2024-02-01 | Ac Immune Sa | Novel compounds |
| AU2023313032A1 (en) | 2022-07-28 | 2025-01-23 | Ac Immune Sa | Novel compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4586950A (en) * | 1982-05-31 | 1986-05-06 | E. I. Du Pont De Nemours & Company | Novel phenyl-substituted sulfonamides |
| US4780125A (en) * | 1982-09-01 | 1988-10-25 | Ciba-Geigy Corporation | N-phenylsulfonyl-N'-triazinylureas |
| DE3927369A1 (de) * | 1989-08-19 | 1991-02-21 | Bayer Ag | Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe |
| US5064851A (en) * | 1990-07-24 | 1991-11-12 | Pfizer Inc. | 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use |
| US5254589A (en) * | 1991-10-15 | 1993-10-19 | Warner-Lambert Company | Sulfonyl urea and carbamate ACAT inhibitors |
| DE4344957A1 (de) * | 1993-12-30 | 1995-07-06 | Hoechst Ag | Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen |
| CN1038679C (zh) * | 1994-12-07 | 1998-06-10 | 南开大学 | 磺酰脲类化合物及其除草用途 |
| HU226462B1 (en) * | 1995-02-17 | 2008-12-29 | Hoechst Ag | Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use |
| AU6967198A (en) * | 1997-04-10 | 1998-10-30 | Eli Lilly And Company | Diarylsulfonylureas for use in treating secretory diarrhea |
-
1997
- 1997-12-29 AT AT97947201T patent/ATE242208T1/de not_active IP Right Cessation
- 1997-12-29 EP EP97947201A patent/EP0964849B1/en not_active Expired - Lifetime
- 1997-12-29 CN CN97181579A patent/CN1127479C/zh not_active Expired - Fee Related
- 1997-12-29 WO PCT/IB1997/001603 patent/WO1998032733A1/en active IP Right Grant
- 1997-12-29 PL PL97335052A patent/PL335052A1/xx unknown
- 1997-12-29 BR BR9714328A patent/BR9714328A/pt not_active Application Discontinuation
- 1997-12-29 ID IDW990764A patent/ID22223A/id unknown
- 1997-12-29 DE DE69722663T patent/DE69722663T2/de not_active Expired - Fee Related
- 1997-12-29 KR KR1019997006786A patent/KR100324058B1/ko not_active IP Right Cessation
- 1997-12-29 EA EA199900603A patent/EA001803B1/ru not_active IP Right Cessation
- 1997-12-29 HU HU0000567A patent/HUP0000567A3/hu unknown
- 1997-12-29 IL IL13085597A patent/IL130855A0/xx unknown
- 1997-12-29 DE DE69729762T patent/DE69729762T2/de not_active Expired - Fee Related
- 1997-12-29 US US09/341,782 patent/US6166064A/en not_active Expired - Fee Related
- 1997-12-29 DK DK97947201T patent/DK0964849T3/da active
- 1997-12-29 CA CA002279186A patent/CA2279186C/en not_active Expired - Fee Related
- 1997-12-29 ES ES02020749T patent/ES2222426T3/es not_active Expired - Lifetime
- 1997-12-29 ES ES97947201T patent/ES2198598T3/es not_active Expired - Lifetime
- 1997-12-29 YU YU33799A patent/YU33799A/sh unknown
- 1997-12-29 TR TR1999/01816T patent/TR199901816T2/xx unknown
- 1997-12-29 AU AU52340/98A patent/AU723895B2/en not_active Ceased
- 1997-12-29 PT PT02020749T patent/PT1270565E/pt unknown
- 1997-12-29 DK DK02020749T patent/DK1270565T3/da active
- 1997-12-29 NZ NZ336248A patent/NZ336248A/xx unknown
- 1997-12-29 CZ CZ19992575A patent/CZ293173B6/cs not_active IP Right Cessation
- 1997-12-29 AT AT02020749T patent/ATE270285T1/de not_active IP Right Cessation
- 1997-12-29 SK SK982-99A patent/SK283679B6/sk unknown
- 1997-12-29 PT PT97947201T patent/PT964849E/pt unknown
- 1997-12-29 JP JP51868798A patent/JP3573757B2/ja not_active Expired - Fee Related
-
1998
- 1998-01-16 PA PA19988444701A patent/PA8444701A1/es unknown
- 1998-01-20 UY UY24861A patent/UY24861A1/es unknown
- 1998-01-23 PE PE1998000051A patent/PE57898A1/es not_active Application Discontinuation
- 1998-01-26 TW TW087101087A patent/TW515788B/zh not_active IP Right Cessation
- 1998-01-27 AR ARP980100358A patent/AR011093A1/es not_active Application Discontinuation
- 1998-01-27 DZ DZ980017A patent/DZ2407A1/xx active
- 1998-01-27 HR HR980045A patent/HRP980045B1/xx not_active IP Right Cessation
- 1998-01-28 MA MA24947A patent/MA26468A1/fr unknown
- 1998-01-28 ZA ZA9800685A patent/ZA98685B/xx unknown
- 1998-01-28 TN TNTNSN98017A patent/TNSN98017A1/fr unknown
- 1998-01-29 AP APAP/P/1998/001190A patent/AP929A/en active
- 1998-01-29 CO CO98004326A patent/CO4920230A1/es unknown
-
1999
- 1999-06-29 IS IS5099A patent/IS5099A/is unknown
- 1999-07-22 BG BG103597A patent/BG103597A/bg unknown
- 1999-07-23 OA OA9900165A patent/OA11079A/en unknown
- 1999-07-28 NO NO19993658A patent/NO313279B1/no not_active IP Right Cessation
-
2000
- 2000-10-31 US US09/703,142 patent/US6433009B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY24861A1 (es) | Derivados de sulfonilurea | |
| AR031248A1 (es) | Compuestos de ditosilato de quinazolina, composicion farmaceutica, metodo de tratamiento y uso en terapia y proceso para la preparacion de dichos compuestos | |
| DE50309979D1 (de) | Neue purinderivate, deren herstelllung und deren verwendung als arzneimittel | |
| BR0014525A (pt) | Processo de tratamento de distúrbios metabólicos, especialmente diabetes, ou uma doença ou condição associada com diabetes | |
| ATE355075T1 (de) | Behandlung der glykogenspeicherkrankheit typ ii | |
| HUP0301749A2 (hu) | Acilfenil-karbamid-származékok, eljárás az elżállításukra és gyógyszerkénti alkalmazásuk | |
| NZ539841A (en) | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | |
| GT200900154A (es) | Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis | |
| CL2004000788A1 (es) | Compuestos derivados de n-[2-oxo-6-(aril o heteroaril)azepan-3-il]-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxamida, antagonistas de los receptores cgrp; composicion farmaceutica; y uso del compuesto en el tratamiento del d | |
| UY28132A1 (es) | Derivados de pirrolopirimidina | |
| PT1173197E (pt) | Intervencao metabolica com glp-1, para melhorar a funcao do tecido isquemico e reperfundido | |
| NO2005015I2 (no) | Terapeutisk aktiv forbindelse preparat inneholdende forbindelsen samt den anvendelse | |
| KR880011142A (ko) | 피페라지닐-헤테로 시클릭 화합물 | |
| RU99105213A (ru) | Применение хелатирующего агента клиохинола для производства фармацевтической композиции для лечения болезни альцгеймера | |
| ECSP066456A (es) | Inhibidores macrocíclicos de la serina proteasa ns3 del virus de la hepatitis c | |
| AR002483A1 (es) | Derivados de naftaleno, procedimientos para la preparacion de los mismos, e intermediarios para los mismos. | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| EA200400664A1 (ru) | Фармацевтические композиции, включающие метформин и глибенкламид, применяемые для лечения сахарного диабета типа ii | |
| UY27503A1 (es) | Nuevos derivados de piperazina | |
| MXPA05002930A (es) | Composiciones para la inhibicion de la proteina cinasa c alfa para el tratamiento de diabetes mellitus y enfermedades cardiovasculares. | |
| NO20055649L (no) | Substituert dihydrokinazolin med antiviale egenskaper | |
| AR035651A1 (es) | Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion | |
| MX2023014630A (es) | Activadores de dimetoxifenilalquilamina de receptores de serotonina. | |
| IT1317048B1 (it) | Uso dell'acido pamoico o di un suo derivato, o di un suo analogo, perla preparazione di un medicamento per il trattamento di patologie | |
| AR037350A1 (es) | Derivados de piperidina, proceso para preparar estos compuestos, composicion farmaceutica, y uso de estos compuestos para la manufactura de un medicamento util para el tratamiento de una enfermedad mediada por ccr5 (tal como artritis reumatoidea) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DESI | Application deemed to be withdrawn |
Effective date: 20071105 |